BRIEF-Spruce Biosciences Presents Phase 1, 2 Data For Tildacerfont In Adults With Congenital Adrenal Hyperplasia From Endocrine Society's 2021 Annual Meeting

Reuters · 03/17/2021 12:31
BRIEF-Spruce Biosciences Presents Phase 1, 2 Data For Tildacerfont In Adults With Congenital Adrenal Hyperplasia From Endocrine Society's 2021 Annual Meeting

- Spruce Biosciences Inc SPRB.O:

  • SPRUCE BIOSCIENCES PRESENTS PHASE 1, 2 DATA FOR TILDACERFONT IN ADULTS WITH CONGENITAL ADRENAL HYPERPLASIA FROM ENDOCRINE SOCIETY'S 2021 ANNUAL MEETING

  • SPRUCE BIOSCIENCES INC - TILDACERFONT LED TO SIGNIFICANT REDUCTIONS IN DISEASE BIOMARKERS OVER 12 WEEKS

  • SPRUCE BIOSCIENCES INC - CAHMELIA PROGRAM UNDERWAY AND IS ENROLLING PATIENTS IN U.S. AND EUROPE

Source text for Eikon: ID:nBw9RbwS2a

Further company coverage: SPRB.O


((Reuters.Briefs@thomsonreuters.com;))